Search
Streptococcus pneumoniae type 17f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10334ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Streptococcus pneumoniae type 19a capsular polysaccharide antigen
go.drugbank.com/drugs/DB10337ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Streptococcus pneumoniae type 23f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10340ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Alipogene tiparvovec
go.drugbank.com/drugs/DB13521ApprovedIt is being investigated for the treatment of lipoprotein lipase (LPL) deficiency.[A259796, A259801, A259806, A259811]
Isoxsuprine
go.drugbank.com/drugs/DB08941ApprovedWithdrawnIt is used in the treatment of peripheral vascular disease and in premature labor.
Adefovir dipivoxil
go.drugbank.com/drugs/DB00718ApprovedIt is ineffective against HIV-1. Adefovir dipivoxil is the diester prodrug of adefovir.
Products: HEPSERA TABLET 10 mg, HEPSERA 10 MG TABLETASRaltegravir
go.drugbank.com/drugs/DB06817ApprovedInvestigationalIt received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Products: Chewable Tablet 25 mg, Chewable Tablet 100 mgFerric oxide
go.drugbank.com/drugs/DB11576ApprovedInvestigationalIt is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite.
Plecanatide
go.drugbank.com/drugs/DB13170ApprovedInvestigationalIt should not be used in children less than six years of age, and should be avoided in patients six years to 18 years of age
Lifileucel
go.drugbank.com/drugs/DB17107ApprovedInvestigationalLifileucel is a tumour-derived autologous T cell immunotherapy composed of a suspension of tumour-derived T cells from the patient [L50171] which undergo isolation, ex vivo expansion, and activation[A263341